Cadence Biomedical appoints Barry R. Hix as Chief Executive Officer
SEATTLE – Today the Board of Directors of Cadence Biomedical announced Barry Hix as the company’s new chief executive officer, effective Dec. 8, 2014. Cadence Biomedical is a developer of medical devices that help individuals accelerate a recovery to walking following a stroke or other neurological condition. The addition of Hix as CEO comes as Cadence expands the use of their first commercial-stage product, Kickstart®. Cadence has shifted to a two-fold strategy: equipping rehabilitation facilities with Kickstart for use in therapy, and offering Kickstart as a prescribed device for continued recovery post-discharge. Hix will succeed co-founder Brian Glaister, who will remain with Cadence Biomedical as the company’s chief operating officer.
During the course of his 25 year career in healthcare, Hix has held executive leadership positions in both public and private companies in the pharmaceutical, healthcare delivery, medical device and healthcare technology industries. Hix’s experience in medical devices includes serving as EVP and General Manager for Empi, a privately held (Blackstone) $200+ million DJO Global company, from 2005 to 2010. His leadership at DJO Global resulted in the expansion of Empi’s orthopedic and recovery-focused product portfolio into new medical condition targets for the company, including stroke. Hix holds a Bachelor’s degree in industrial management from the Georgia Institute of Technology, a Master’s in marketing from Georgia State University and a Master’s in public health from Emory University.
“Cadence has the unique opportunity to transform patients’ lives, enabling them to return to a lifestyle empowered by a recovery to walking,” said Hix. “I am extremely excited to join the Cadence team and begin the important work to expand our footprint, both here in the U.S. and internationally. I look forward to working closely with the healthcare professionals dedicated to helping individuals recover from strokes and other neurological conditions.”
“Barry brings tremendous experience as a commercial leader in this medical device segment to a dedicated team of talented professionals,” said Michael Hovanes, Chairman of the Board. “His proven track record of driving adoption across the healthcare landscape will enable Kickstart and our pipeline products to achieve commercial success and, more importantly, equip healthcare professionals with tools to return patients to walking. I look forward to working with Barry to build and grow Cadence Biomedical.”
About Cadence Biomedical
Cadence Biomedical, a commercial-stage medical device company headquartered in Seattle, Washington, is committed to working with healthcare professionals, patients and caregivers to advance neurorehabilitation. The company’s primary commercial product, Kickstart, is a neurorehabilitation device designed to accelerate a recovery to walking in stroke, multiple sclerosis, spinal cord injury patients and in individuals with other progressive neurological conditions. Kickstart is available for use in physical therapy during the initial recovery process and as a prescribed device for post-discharge use in the community and home settings.